IL-5 directly activates lung fibroblasts to drive airway remodelling in severe asthma through ECM deposition, MMP/TIMP imbalance, and pro-fibrotic cytokine secretion, positioning it as a dual mediator of inflammation and fibrosis with novel therapeutic potential. The gene discussed is IL5; the disease is asthma.